Cite
HARVARD Citation
Elsisi, G. et al. (2020). Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt. Journal of medical economics. pp. 575-580. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Elsisi, G. et al. (2020). Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt. Journal of medical economics. pp. 575-580. [Online].